<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Clinical approach to Staphylococcus aureus bacteremia in adults
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Clinical approach to Staphylococcus aureus bacteremia in adults
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Clinical approach to Staphylococcus aureus bacteremia in adults
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Vance G Fowler, Jr, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Thomas L Holland, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Steven Tong, MBBS, Hons, FRACP, PhD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Elinor L Baron, MD, DTMH
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Dec 14, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         <em>
          Staphylococcus aureus
         </em>
         is a leading cause of community-acquired and hospital-acquired bacteremia. Issues related to clinical manifestations of
         <em>
          S. aureus
         </em>
         infection are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/2135.html" rel="external">
          "Clinical manifestations of Staphylococcus aureus infection in adults"
         </a>
         .)
        </p>
        <p>
         Issues related to the clinical approach to
         <em>
          S. aureus
         </em>
         bacteremia in adults with no cardiac device or prosthetic valve will be reviewed here. Issues related to evaluation of patients with a cardiac device or prosthetic valve are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/2146.html" rel="external">
          "Infections involving cardiac implantable electronic devices: Epidemiology, microbiology, clinical manifestations, and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2138.html" rel="external">
          "Prosthetic valve endocarditis: Epidemiology, clinical manifestations, and diagnosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H21662697">
         <span class="h1">
          CLINICAL APPROACH
         </span>
         <span class="headingEndMark">
          —
         </span>
         The clinical approach to
         <em>
          S. aureus
         </em>
         bacteremia consists of careful history and physical examination, infectious disease consultation, and diagnostic evaluation including echocardiography and additional imaging as needed.
        </p>
        <p class="headingAnchor" id="H21662703">
         <span class="h2">
          History and physical examination
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          History
         </strong>
         – A careful history and physical examination is essential. For circumstances in which the source of bacteremia is uncertain, patients should be questioned carefully regarding potential portals of entry including recent skin or soft tissue infection and presence of indwelling prosthetic devices (including intravascular catheters, orthopedic hardware, and cardiac devices).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Patients should also be questioned regarding symptoms that may reflect metastatic infection, which can occur in up to 40 percent of cases [
         <a href="#rid1">
          1
         </a>
         ]. These include bone or joint pain (particularly back pain, suggesting vertebral osteomyelitis, discitis, and/or epidural abscess), protracted fever and/or sweats (suggestive of endocarditis), abdominal pain (particularly left upper quadrant pain, which may reflect splenic infarction), costovertebral angle tenderness (which may reflect renal infarction or psoas abscess), and headache (which may reflect septic emboli).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Physical examination
         </strong>
         – The physical examination should include careful cardiac examination for signs of new murmurs or heart failure. A vigorous search should be undertaken for the clinical stigmata of endocarditis, including evidence of small and large emboli with special attention to the fundi, conjunctivae, skin, and digits. A neurologic evaluation should be undertaken for evidence of focal neurologic impairment; it is also important as a baseline examination should neurologic deficits develop later. These issues are discussed further separately. (See
         <a class="medical medical_review" href="/z/d/html/2143.html" rel="external">
          "Clinical manifestations and evaluation of adults with suspected left-sided native valve endocarditis", section on 'Clinical manifestations'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Serial bedside examinations are critical for detection of complications that may develop after initial evaluation and during the course of treatment. Metastatic seeding may occur within the first few days of hospitalization, although in some cases it may not come to clinical attention for several weeks. In several case series, only 39 percent of 133 patients with bacteremic
         <em>
          S. aureus
         </em>
         vertebral osteomyelitis [
         <a href="#rid2">
          2
         </a>
         ] and 57 percent of 35 patients with epidural abscess [
         <a href="#rid3">
          3
         </a>
         ] had a diagnosis on admission related to the spine. Failure to identify such complications of
         <em>
          S. aureus
         </em>
         bacteremia may lead to catastrophic complications (eg, death, paralysis) [
         <a href="#rid4">
          4
         </a>
         ] or relapsing bacteremia due to inadequate treatment [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H21662710">
         <span class="h2">
          Infectious disease consultation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Bedside infectious disease consultation is an important component of management for patients with
         <em>
          S. aureus
         </em>
         bacteremia and should occur whenever feasible, given the importance of serial examination to evaluate for metastatic infection and/or clues to the source of bacteremia.
        </p>
        <p>
         Several studies have demonstrated bedside infectious disease consultation is associated with better outcomes including fewer deaths, fewer relapses, and lower readmission rates than telephone consultation or no consultation [
         <a href="#rid6">
          6-11
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a retrospective study comparing bedside consultation with telephone consultation for management of 342 patients with
         <em>
          S. aureus
         </em>
         bacteremia, bedside consultation was associated with a lower 90-day mortality (9 versus 29 percent; odds ratio [OR] 0.25, 95% CI 0.13-0.51) [
         <a href="#rid8">
          8
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In another study including 244 patients with
         <em>
          S. aureus
         </em>
         bacteremia, fewer relapses were observed among those who received bedside consultation (6 versus 18 percent), even among patients treated with an appropriate duration of therapy [
         <a href="#rid7">
          7
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a randomized crossover clinical trial in Germany, unsolicited telephone consultations for
         <em>
          S. aureus
         </em>
         bacteremia did not improve 30-day mortality [
         <a href="#rid12">
          12
         </a>
         ]. However, the study was underpowered given low overall mortality (approximately 5 percent).
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H12011336">
         <span class="h2">
          Diagnostic evaluation
         </span>
         <span class="headingEndMark">
          —
         </span>
         The diagnostic evaluation should include blood cultures, echocardiography, and additional imaging tailored to individual circumstances, as outlined below. Other studies include routine laboratory tests and electrocardiography.
        </p>
        <p class="headingAnchor" id="H1098069970">
         <span class="h3">
          Blood cultures
         </span>
        </p>
        <p class="headingAnchor" id="H3980321429">
         <span class="h4">
          Interpreting results
         </span>
         <span class="headingEndMark">
          —
         </span>
         Blood culture detection of Staphylococcus aureus should always be regarded as clinically significant, even if only a single positive blood culture bottle is observed [
         <a href="#rid13">
          13
         </a>
         ]. Identification of positive blood cultures should prompt initiation of empiric therapy as well as further clinical evaluation.
        </p>
        <p class="headingAnchor" id="H2353985245">
         <span class="h4">
          Follow-up blood cultures
         </span>
         <span class="headingEndMark">
          —
         </span>
         Blood cultures should be drawn every 24 to 48 hours until clearance is demonstrated.
        </p>
        <p>
         Persistent
         <em>
          S. aureus
         </em>
         bacteremia despite appropriate antibiotic therapy is prognostically important. In a large European cohort including more than 900 patients, duration of bacteremia at least one additional day after starting appropriate antibiotic therapy was observed in 32 percent of cases; among such patients, the 30-day mortality was double that of the patients whose blood cultures cleared immediately (28 versus 13 percent) [
         <a href="#rid14">
          14
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H21662716">
         <span class="h3">
          Echocardiography
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with
         <em>
          S. aureus
         </em>
         bacteremia should undergo echocardiography to evaluate for presence of endocarditis [
         <a href="#rid15">
          15,16
         </a>
         ]. The approach for patients with no cardiac device or prosthetic device is discussed below.
        </p>
        <p>
         Issues related to evaluation of patients with a cardiac device or prosthetic valve are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/2146.html" rel="external">
          "Infections involving cardiac implantable electronic devices: Epidemiology, microbiology, clinical manifestations, and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2138.html" rel="external">
          "Prosthetic valve endocarditis: Epidemiology, clinical manifestations, and diagnosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3889274397">
         <span class="h4">
          Initial evaluation with TTE
         </span>
         <span class="headingEndMark">
          —
         </span>
         Transthoracic echocardiography (TTE) is usually performed first [
         <a href="#rid16">
          16
         </a>
         ]; identification of a vegetation on TTE may obviate the need for transesophageal echocardiography (TEE), although TTE is not sufficient for ruling out infective endocarditis (IE) [
         <a href="#rid17">
          17,18
         </a>
         ].
        </p>
        <p>
         The results of echocardiography are useful even when the study is negative, as the absence of IE may impact decisions about the duration of antimicrobial therapy. In one series including 103 patients with
         <em>
          S. aureus
         </em>
         bacteremia, the diagnosis of endocarditis was established by TTE and TEE in 7 versus 25 percent of cases, respectively [
         <a href="#rid19">
          19
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3374024747">
         <span class="h4">
          Indications for TEE
         </span>
         <span class="headingEndMark">
          —
         </span>
         The indications for TEE in patients with
         <em>
          S. aureus
         </em>
         bacteremia and no evidence of vegetation on TTE are controversial [
         <a href="#rid20">
          20,21
         </a>
         ]. TEE is substantially more sensitive than TTE for identification of valvular vegetation [
         <a href="#rid18">
          18,22-24
         </a>
         ]; it is most sensitive when performed five to seven days after the onset of bacteremia [
         <a href="#rid25">
          25,26
         </a>
         ]. In the setting of high clinical suspicion for IE and a negative echocardiogram, a repeat study is warranted. However, TEE has associated costs and risks; major complications such as esophageal perforation occur in approximately 1 in 5000 procedures [
         <a href="#rid27">
          27
         </a>
         ].
        </p>
        <p>
         Pursuit of TEE is important in the setting of risk factors for IE; these include [
         <a href="#rid17">
          17,28
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Persistent
         <em>
          S. aureus
         </em>
         bacteremia despite appropriate antimicrobial therapy
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Short time to blood culture positivity (ie, within 24 to 48 hours rather than at later time points) [
         <a href="#rid29">
          29,30
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Unknown duration of bacteremia (ie, community-acquired infection)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Presence of cardiac prosthetic material
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Presence of predisposing valvular abnormality
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Absence of evident removable source of bacteremia
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hemodialysis dependency [
         <a href="#rid31">
          31
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Presence of peripheral stigmata for IE
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Intravenous drug use
        </p>
        <p>
        </p>
        <p>
         A number of clinical prediction rules have been developed to quantify the risk of endocarditis among patients wi
         <em>
          th S. aureus
         </em>
         bacteremia; thus far, evidence supporting use of the VIRSTA score is most favorable  (
         <a class="graphic graphic_table graphicRef131171" href="/z/d/graphic/131171.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid29">
          29,32-35
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The VIRSTA score was derived from a prospective cohort study including more than 2000 patients with
         <em>
          S. aureus
         </em>
         bacteremia to assess variables independently associated with IE  (
         <a class="graphic graphic_table graphicRef131171" href="/z/d/graphic/131171.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid33">
          33
         </a>
         ]. The findings suggest that TEE it may be reasonable to forgo TEE for patients with VIRSTA score ≤2; this score had a negative predictive value (NPV) of 98.8 percent (95% CI 98.4-99.4). In a validation study including 922 patients, 62 were diagnosed with IE; the sensitivity and NPV of the VIRSTA score were 96.7 and 99.5 percent, respectively [
         <a href="#rid36">
          36
         </a>
         ]. In a survey of more than 650 infectious disease experts, a majority of respondents favored TEE for VIRSTA score ≥3 [
         <a href="#rid37">
          37
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The PREDICT tool uses a combination of day 1 and day 5 variables (cardiac device, community- versus health care-associated versus nosocomial infection, and duration of bacteremia) to identify patients most likely to benefit from TEE [
         <a href="#rid34">
          34,38
         </a>
         ]. In a validation study including 922 patients, 62 were diagnosed with IE; the sensitivity and NPV for the PREDICT scale on day 5 were 51.6 and 95.1 percent, respectively [
         <a href="#rid36">
          36
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a prospective study including 477 patients with
         <em>
          S. aureus
         </em>
         bacteremia in the Netherlands, the accuracy of the POSITIVE, PREDICT, and VIRSTA scores were compared [
         <a href="#rid39">
          39
         </a>
         ]. The VIRSTA score was the most accurate (NPV 99.3 percent); approximately 70 percent of patients with
         <em>
          S. aureus
         </em>
         bacteremia were classified as high risk for endocarditis, warranting TEE.
        </p>
        <p>
        </p>
        <p>
         For patients with IE complications warranting an extended course of parenteral antibiotic therapy (such as osteomyelitis, discitis, or epidural abscess), in the absence of concern for cardiac complications based on clinical findings and TTE, it may be reasonable to forgo TEE.
        </p>
        <p class="headingAnchor" id="H12011469">
         <span class="h3">
          Additional imaging
         </span>
         <span class="headingEndMark">
          —
         </span>
         Imaging should be tailored to findings on history and physical examination.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Back pain
         </strong>
         – Patients with back pain should be evaluated for vertebral osteomyelitis and discitis; this is discussed further separately. (See
         <a class="medical medical_review" href="/z/d/html/7663.html" rel="external">
          "Vertebral osteomyelitis and discitis in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Headache or focal neurologic signs
         </strong>
         – Patients with headache or focal neurologic signs or symptoms in the setting of known or suspected IE should undergo magnetic resonance imaging of the head. (See
         <a class="medical medical_review" href="/z/d/html/2143.html" rel="external">
          "Clinical manifestations and evaluation of adults with suspected left-sided native valve endocarditis", section on 'Additional evaluation for IE source or complications'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Abdominal symptoms and subclinical sites of metastatic infection
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Computed tomography (CT)
         </strong>
         – CT of the torso should be pursued for patients with abdominal pain or costovertebral angle tenderness (to evaluate for presence of splenic infarct, renal infarct, psoas abscess, or other intra-abdominal sites of infection). Such imaging may also be appropriate for patients in whom an unrecognized focus of infection is suspected (such as persistent fever or bacteremia despite appropriate antimicrobial therapy).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Positron emission tomography/computed tomography (PET/CT)
         </strong>
         – PET/CT is a promising modality to evaluate for metastatic infection. In a prospective cohort study including more than 300 patients with
         <em>
          S. aureus
         </em>
         bacteremia (of whom half underwent PET/CT one to two weeks after diagnosis), PET/CT demonstrated a new focus of infection in almost half of cases, most commonly at osteoarticular sites; 90-day mortality was lower in the PET/CT group (13.9 versus 28.5 percent) [
         <a href="#rid40">
          40
         </a>
         ]. In a subsequent review including 7 observational studies and 1300 patients with
         <em>
          S. aureus
         </em>
         bacteremia, use of PET/CT frequently provided clinically meaningful results that influenced patient management; numbers needed to treat to prevent death, modify antimicrobial therapy, or pursue further source control were 4 to 8, 7 to 9, and 10 to 27, respectively [
         <a href="#rid41">
          41
         </a>
         ]. However, subsequent authors have suggested that the observed impact of PET/CT on mortality may have been confounded by immortal time bias [
         <a href="#rid42">
          42
         </a>
         ]; further randomized trial data are needed.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h1">
          MANAGEMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         Management of
         <em>
          S. aureus
         </em>
         bacteremia consists of prompt source control and antimicrobial therapy [
         <a href="#rid43">
          43,44
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2942866469">
         <span class="h2">
          Source control
         </span>
         <span class="headingEndMark">
          —
         </span>
         Source control refers to surgical or procedural management of an infected site with the intent of mitigating a potential source of a patient’s systemic infection; it may include incision and drainage, and/or removal of infected prosthetic devices. (See
         <a class="medical medical_review" href="/z/d/html/3813.html" rel="external">
          "Intravascular non-hemodialysis catheter-related infection: Clinical manifestations and diagnosis"
         </a>
         .)
        </p>
        <p>
         Early source control is a cornerstone of management for
         <em>
          S. aureus
         </em>
         bacteremia. In an observational study including more than 800 patients with
         <em>
          S. aureus
         </em>
         bacteremia (of whom 63 percent had short duration [1 to 2 days], 28 percent had intermediate duration [3 to 6 days], and 9 percent had prolonged duration [≥7 days]), the time to source-control procedure was delayed in the prolonged and intermediate groups compared with the short group (3.5 days, 3 days, and 1 day, respectively); each continued day of bacteremia was associated with a relative risk of death of 1.16 (95% CI 1.1-1.2) [
         <a href="#rid44">
          44
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h2">
          Empiric antibiotic therapy
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical approach
         </strong>
         – The optimal approach to empiric therapy in the setting of
         <em>
          S. aureus
         </em>
         bacteremia prior to availability of culture and susceptibility data is uncertain. We favor empiric antimicrobial therapy with activity against methicillin-resistant
         <em>
          S. aureus
         </em>
         (MRSA), rather than empiric therapy with activity against both MRSA and methicillin-sensitive
         <em>
          S. aureus
         </em>
         (MSSA)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Empiric treatment for MRSA
         </strong>
         – Empiric treatment for MRSA consists of
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         (
         <a class="graphic graphic_table graphicRef128911" href="/z/d/graphic/128911.html" rel="external">
          table 2
         </a>
         );
         <a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">
          daptomycin
         </a>
         (8 to 10 mg/kg intravenously once daily) is an alternative agent.
         <a class="drug drug_general" data-topicid="9001" href="/z/d/drug information/9001.html" rel="external">
          Ceftobiprole
         </a>
         is also a potential alternative agent; thus far it is not available in the United States. (See
         <a class="medical medical_review" href="/z/d/html/3164.html" rel="external">
          "Methicillin-resistant Staphylococcus aureus (MRSA) in adults: Treatment of bacteremia", section on 'Monotherapy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Once susceptibility results are available, if the isolate is methicillin-sensitive
         <em>
          S. aureus
         </em>
         (MSSA), antibiotic treatment should be de-escalated to a beta-lactam agent (such as
         <a class="drug drug_general" data-topicid="9674" href="/z/d/drug information/9674.html" rel="external">
          nafcillin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9724" href="/z/d/drug information/9724.html" rel="external">
          oxacillin
         </a>
         , flucloxacillin, or
         <a class="drug drug_general" data-topicid="9214" href="/z/d/drug information/9214.html" rel="external">
          cefazolin
         </a>
         ) as discussed below. (See
         <a class="local">
          'Methicillin-sensitive S. aureus'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Limited support for empiric inclusion of targeted treatment for MSSA
         </strong>
         – In addition to empiric treatment for MRSA, some favor inclusion of an antimicrobial agent with targeted activity against MSSA [
         <a href="#rid45">
          45-47
         </a>
         ]. Among patients with the highest risk of morbidity and mortality from
         <em>
          S. aureus
         </em>
         infection (including patients with severe sepsis, probable endocarditis, or presence of a prosthetic or intravascular device), there are data suggesting that initial
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         monotherapy with subsequent de-escalation to a beta-lactam agent for patients with MSSA may result in worse outcomes than initial empiric therapy with two agents (targeting MRSA and MSSA, respectively) [
         <a href="#rid45">
          45,48-50
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         However, a retrospective study including more than 5000 patients with MSSA bacteremia who received empiric monotherapy with a beta-lactam or
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         noted no difference in all-cause 30-day mortality, even though there was a significantly better outcome for the same cohort of patients who received definitive therapy with a beta-lactam from day 4 to 14 of treatment [
         <a href="#rid51">
          51
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H611553532">
         <span class="h2">
          Tailoring antibiotic therapy
         </span>
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h3">
          Methicillin-sensitive S. aureus
         </span>
        </p>
        <p class="headingAnchor" id="H3426132116">
         <span class="h4">
          Clinical approach
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Tailoring to beta-lactam therapy
         </strong>
         – Treatment of MSSA bacteremia generally consists of a beta-lactam agent such as
         <a class="drug drug_general" data-topicid="9674" href="/z/d/drug information/9674.html" rel="external">
          nafcillin
         </a>
         (2 g IV every four hours),
         <a class="drug drug_general" data-topicid="9724" href="/z/d/drug information/9724.html" rel="external">
          oxacillin
         </a>
         (2 g IV every four hours), flucloxacillin (2 g IV every six hours), or
         <a class="drug drug_general" data-topicid="9214" href="/z/d/drug information/9214.html" rel="external">
          cefazolin
         </a>
         (2g IV every eight hours) [
         <a href="#rid52">
          52
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         If the isolate is penicillin sensitive, benzylpenicillin (4 million units intravenously [IV] every four hours) may be used for treatment
         <em>
          of S. aureus
         </em>
         bacteremia [
         <a href="#rid53">
          53
         </a>
         ]. Historically, penicillin-susceptib
         <em>
          le S. aureus
         </em>
         isolates are relatively rare [
         <a href="#rid54">
          54
         </a>
         ]; however, some studies have reported an increase in prevalence [
         <a href="#rid55">
          55,56
         </a>
         ]. However, phenotypic susceptibility testing methods may not reliably detect penicillinase production [
         <a href="#rid57">
          57
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Outpatient treatment
         </strong>
         – For continuation of intravenous therapy in outpatient settings,
         <a class="drug drug_general" data-topicid="9214" href="/z/d/drug information/9214.html" rel="external">
          cefazolin
         </a>
         may be more practical and better tolerated than antistaphylococcal penicillins [
         <a href="#rid58">
          58,59
         </a>
         ]. There are no adequately powered prospective clinical trials comparing the efficacy of various beta-lactam agents for treatment of MSSA bacteremia; retrospective data suggest that cefazolin and antistaphylococcal penicillins are equally effective [
         <a href="#rid60">
          60-63
         </a>
         ]. One retrospective study suggested that patients who received cefazolin had a lower risk of mortality and similar risk of recurrent infection compared with those who received
         <a class="drug drug_general" data-topicid="9724" href="/z/d/drug information/9724.html" rel="external">
          oxacillin
         </a>
         or
         <a class="drug drug_general" data-topicid="9674" href="/z/d/drug information/9674.html" rel="external">
          nafcillin
         </a>
         [
         <a href="#rid64">
          64
         </a>
         ]; however, interpretation of the findings is limited by potential confounding.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="9214" href="/z/d/drug information/9214.html" rel="external">
          Cefazolin
         </a>
         <strong>
          inoculum effect of uncertain significance
         </strong>
         – Cefazolin has been observed to demonstrate an inoculum effect among a subset of isolates; this is defined as an increase in the cefazolin minimum inhibitory concentration (MIC) at high inoculum (10
         <sup>
          7
         </sup>
         colony-forming units [CFU]/mL) compared with standard inoculum (10
         <sup>
          5
         </sup>
         CFU/mL) [
         <a href="#rid65">
          65,66
         </a>
         ]. The clinical significance of this phenomenon is uncertain; studies examining the impact of this effect have produced conflicting results [
         <a href="#rid67">
          67,68
         </a>
         ]. In one study including 89 isolates from 77 patients (55 percent of which demonstrated the inoculum effect) treated with cefazolin, a higher 30-day mortality was observed among patients with strains demonstrating the inoculum effect than patients with strains demonstrating no inoculum effect (risk ratio 2.65, 95% CI 1.1-6.4) [
         <a href="#rid65">
          65
         </a>
         ]. However, other studies have not observed a clinical difference in outcomes [
         <a href="#rid69">
          69,70
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Beta-lactam allergy
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          Vancomycin
         </a>
         – Vancomycin is less effective for treatment of
         <em>
          S. aureus
         </em>
         bacteremia than beta-lactam agents and should not be administered as primary therapy for methicillin-sensitive strains unless the use of a beta-lactam agent is precluded by drug intolerance [
         <a href="#rid71">
          71-80
         </a>
         ]. Patients with MSSA bacteremia and a reported penicillin allergy should have treatment guided by allergy history (
         <a class="drug drug_general" data-topicid="9214" href="/z/d/drug information/9214.html" rel="external">
          cefazolin
         </a>
         may be given if history excludes anaphylactic features) or, if available, full allergy evaluation with skin testing or oral challenge [
         <a href="#rid81">
          81,82
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         In an observational study of 505 patients wi
         <em>
          th S. aureus
         </em>
         bacteremia,
         <a class="drug drug_general" data-topicid="9674" href="/z/d/drug information/9674.html" rel="external">
          nafcillin
         </a>
         was superior to
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         for preventing relapse or persistent MSSA bacteremia; the failure rate was 4 versus 20 percent [
         <a href="#rid77">
          77
         </a>
         ]. In another study of 294 patients wi
         <em>
          th S. aureus
         </em>
         bacteremia, vancomycin therapy was associated with a higher risk of relapse (odds ratio 4.1, 95% CI 1.5-11.6) [
         <a href="#rid72">
          72
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Alternative agents
         </strong>
         – Alternative agents for the treatment of
         <em>
          S. aureus
         </em>
         bacteremia should be reserved for patients who are intolerant to beta-lactams and
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         , and should be guided by the results of susceptibility testing. The use of these agents is discussed further separately. (See
         <a class="medical medical_review" href="/z/d/html/3164.html" rel="external">
          "Methicillin-resistant Staphylococcus aureus (MRSA) in adults: Treatment of bacteremia", section on 'Antimicrobial therapy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Patients who require treatment with an alternative agent should be managed by clinicians who are experts in the treatment of infectious diseases and who are familiar with the available (and limited) literature on the efficacy, dosing, and side effects of such therapy. The use of all alternative agents is limited because of the development of resistance or an increased rate of adverse effects during therapy.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3018413305">
         <span class="h4">
          No role for routine combination therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         There is no role for routine combination therapy of antistaphylococcal penicillins or
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         with aminoglycosides,
         <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">
          rifampin
         </a>
         , or
         <a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">
          daptomycin
         </a>
         for treatment of staphylococcal bacteremia:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Routine combination of antistaphylococcal penicillins or
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         with aminoglycosides is not warranted. While in vitro and experimental models of endocarditis have demonstrated that combination therapy facilitates more rapid killing of MSSA than monotherapy, the evidence for clinically significant benefit is minimal.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         This was illustrated by a randomized trial of 48 patients with MSSA native valve endocarditis [
         <a href="#rid83">
          83
         </a>
         ]. While patients who received
         <a class="drug drug_general" data-topicid="9674" href="/z/d/drug information/9674.html" rel="external">
          nafcillin
         </a>
         plus
         <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">
          gentamicin
         </a>
         for the first two weeks of therapy had more rapid clearance of bacteremia than those who received nafcillin alone, cure rates were comparable and combination therapy was associated with a higher incidence of renal dysfunction. (See
         <a class="medical medical_review" href="/z/d/html/2152.html" rel="external">
          "Antimicrobial therapy of left-sided native valve endocarditis", section on 'Staphylococci'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Subsequently, a randomized trial including 236 patients wit
         <em>
          h S. aureus
         </em>
         bacteremia and endocarditis demonstrated that
         <a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">
          daptomycin
         </a>
         monotherapy is not inferior to low-dose
         <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">
          gentamicin
         </a>
         plus an antistaphylococcal penicillin or
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         ; those in the standard therapy arm experienced significantly more renal impairment than those in the daptomycin arm [
         <a href="#rid84">
          84
         </a>
         ]. An investigation of safety data from the trial noted significantly greater reduction in creatinine clearance among those who received initial low-dose gentamicin than those who did not (22 versus 8 percent, respectively) [
         <a href="#rid85">
          85
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         There is no role for adjunctive
         <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">
          rifampin
         </a>
         for treatment of
         <em>
          S. aureus
         </em>
         bacteremia in the absence of prosthetic valve endocarditis or orthopedic hardware. In a randomized trial including more than 700 adults with
         <em>
          S. aureus
         </em>
         bacteremia (only 14 of whom had a prosthetic valve or prosthetic joint) randomly assigned to treatment with standard therapy plus rifampin (600 or 900 mg per day, orally or intravenously) or placebo, no significant difference in mortality or bacteriologic failure was observed after 12 weeks (17 versus 18 percent; hazard ratio 0.96, CI 0.68-1.35) [
         <a href="#rid86">
          86
         </a>
         ]. In addition, patients treated with rifampin were more likely to have adverse drug interactions than those who received placebo.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Issues related to use of adjunctive
         <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">
          rifampin
         </a>
         for treatment of staphylococcal infection in the context of prosthetic valve endocarditis or orthopedic hardware are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/2141.html" rel="external">
          "Antimicrobial therapy of prosthetic valve endocarditis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7665.html" rel="external">
          "Prosthetic joint infection: Treatment", section on 'Use of adjunctive rifampin'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         There is no role for adjunctive
         <a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">
          daptomycin
         </a>
         for the treatment of MSSA bacteremia. In a randomized trial including more than 100 patients with MSSA bacteremia treated with an anti-staphylococcal beta-lactam in combination with daptomycin or placebo, addition of daptomycin did not shorten duration of bacteremia or improve clinical outcomes [
         <a href="#rid87">
          87
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h3">
          Methicillin-resistant S. aureus
         </span>
         <span class="headingEndMark">
          —
         </span>
         The treatment of patients with bacteremia due to MRSA is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/3164.html" rel="external">
          "Methicillin-resistant Staphylococcus aureus (MRSA) in adults: Treatment of bacteremia", section on 'Antimicrobial therapy'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H12011616">
         <span class="h2">
          Follow-up cultures
         </span>
         <span class="headingEndMark">
          —
         </span>
         Once the diagnosis of
         <em>
          S. aureus
         </em>
         bacteremia has been established and treatment has been initiated, blood cultures should be repeated to document clearance of bacteremia. At least one blood culture set with an adequate volume of 8 to 10 mL per bottle should be collected; a single blood culture bottle may not be sufficient to demonstrate resolution of bacteremia [
         <a href="#rid88">
          88,89
         </a>
         ].
        </p>
        <p>
         Failure to clear bacteremia within 48 hours after initiation of therapy should prompt further evaluation, including evaluation of susceptibility data to ensure appropriate antibiotic selection and dosing, as well as clinical evaluation for occult focus of infection that may require drainage or other intervention beyond antimicrobial therapy alone.
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h2">
          Completing antibiotic therapy
         </span>
        </p>
        <p class="headingAnchor" id="H3431684710">
         <span class="h3">
          Parenteral versus oral therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with uncomplicated
         <em>
          S. aureus
         </em>
         bacteremia, parenteral therapy remains standard treatment. In carefully selected patients, it is possible that treatment may be completed successfully with an oral antibiotic regimen; however, this approach requires further evaluation in well-designed clinical trials before it can be considered standard of care [
         <a href="#rid90">
          90
         </a>
         ].
        </p>
        <p>
         Some data supporting the potential utility of oral stepdown therapy for patients with
         <em>
          S. aureus
         </em>
         bacteremia were provided by the trial of partial oral treatment of endocarditis (POET trial) for carefully selected patients with left-sided endocarditis [
         <a href="#rid91">
          91
         </a>
         ]. In the full cohort study, partial oral treatment was noninferior to full parenteral therapy; however, generalizability to patients with
         <em>
          S. aureus
         </em>
         bacteremia is limited since only 22 percent of the cohort had
         <em>
          S. aureus
         </em>
         infective endocarditis and none were infected with MRSA.
        </p>
        <p class="headingAnchor" id="H1554499783">
         <span class="h3">
          Duration of therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         The duration of therapy for
         <em>
          S. aureus
         </em>
         bacteremia depends on the etiology of infection [
         <a href="#rid7">
          7
         </a>
         ]. Determination of treatment duration requires differentiation of patients with uncomplicated
         <em>
          S aureus
         </em>
         bacteremia (who may be treated with 14 days of intravenous therapy) from patients with complicated
         <em>
          S. aureus
         </em>
         bacteremia
         <em>
          (
         </em>
         who require longer duration of intravenous treatment) [
         <a href="#rid15">
          15
         </a>
         ].
        </p>
        <p>
         In general, a patient may be presumed to have uncomplicated
         <em>
          S. aureus
         </em>
         bacteremia if all of the following criteria are met [
         <a href="#rid16">
          16,92,93
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Infective endocarditis has been excluded via echocardiography. (See
         <a class="local">
          'Echocardiography'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         No indwelling devices (such as prosthetic heart valves or vascular grafts) are present.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Follow-up blood cultures drawn two to four days after initiating intravenous antistaphylococcal therapy and removing the presumed focus of infection (if present) are negative.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The patient defervesced within 48 to 72 hours after initiating intravenous antistaphylococcal therapy and removal of the presumed focus of infection (such as debridement of soft tissue infection or intravascular catheter removal).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         There is no evidence of metastatic staphylococcal infection on physical examination.
        </p>
        <p>
        </p>
        <p>
         Patients meeting all of these criteria may be treated with 14 days of effective antimicrobial therapy from the first negative blood culture. These patients should have negative surveillance blood cultures within 72 hours after initiation of appropriate antimicrobial therapy and no signs of ongoing systemic staphylococcal infection. Use of an algorithm to guide management of staphylococcal bacteremia may be useful to optimize duration of antibiotic therapy [
         <a href="#rid94">
          94
         </a>
         ].
        </p>
        <p>
         It is uncertain whether a shorter treatment duration (&lt;14 days) may be appropriate for some patients with uncomplicated methicillin-sensitive
         <em>
          S. aureus
         </em>
         bacteremia. In one retrospective cohort of carefully selected low-risk patients in Denmark, outcomes were similar for shorter (6 to 10 days) and longer (13 to 15 days) treatment duration; however, mortality even among the low-risk patients was high (17 to 23 percent); further study of treatment duration is needed [
         <a href="#rid95">
          95,96
         </a>
         ].
        </p>
        <p>
         Patients with
         <em>
          S. aureus
         </em>
         bacteremia who do not meet all of the above criteria should be presumed to have a deep focus of infection, warranting intravenous treatment for longer than two weeks. The duration of therapy for such patients depends on the nature of the underlying infection, as discussed in the following sections:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Infective endocarditis (see
         <a class="medical medical_review" href="/z/d/html/2152.html" rel="external">
          "Antimicrobial therapy of left-sided native valve endocarditis"
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cardiac device infection (see
         <a class="medical medical_review" href="/z/d/html/116021.html" rel="external">
          "Infections involving cardiac implantable electronic devices: Treatment and prevention"
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Osteomyelitis (see
         <a class="medical medical_review" href="/z/d/html/114350.html" rel="external">
          "Nonvertebral osteomyelitis in adults: Treatment"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7663.html" rel="external">
          "Vertebral osteomyelitis and discitis in adults"
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Prosthetic joint infection (see
         <a class="medical medical_review" href="/z/d/html/7665.html" rel="external">
          "Prosthetic joint infection: Treatment"
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Septic arthritis (see
         <a class="medical medical_review" href="/z/d/html/7666.html" rel="external">
          "Septic arthritis in adults"
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Meningitis (see
         <a class="medical medical_review" href="/z/d/html/1283.html" rel="external">
          "Treatment of bacterial meningitis caused by specific pathogens in adults"
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Pneumonia (see
         <a class="medical medical_review" href="/z/d/html/6993.html" rel="external">
          "Treatment of hospital-acquired and ventilator-associated pneumonia in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7027.html" rel="external">
          "Treatment of community-acquired pneumonia in adults who require hospitalization"
         </a>
         )
        </p>
        <p>
        </p>
        <p>
         Issues related to the likelihood of hardware seeding during
         <em>
          S. aureus
         </em>
         bacteremia are discussed further separately. (See
         <a class="medical medical_review" href="/z/d/html/2135.html" rel="external">
          "Clinical manifestations of Staphylococcus aureus infection in adults", section on 'Prosthetic joint infection'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H21667325">
         <span class="h1">
          PROGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         A systematic review including 341 studies noted mortality rates are &gt;25 percent at three months [
         <a href="#rid97">
          97
         </a>
         ]. Mortality is higher among patients with underlying comorbidities, methicillin-resistant
         <em>
          S. aureus
         </em>
         (MRSA) infection (odds ratio [OR] 9.3, 95% CI 1.5-59.2), and/or time to positivity of blood cultures ≤12 hours (OR 6.9, 95% CI 1.1-44.7) [
         <a href="#rid97">
          97-101
         </a>
         ].
        </p>
        <p>
         Treatment failure (ie, death within 30 days following treatment, persistent bacteremia &gt;10 days after initiation of appropriate therapy, or recurrence of bacteremia within 60 days of discontinuing therapy) and hospital readmission are common in patients with
         <em>
          S. aureus
         </em>
         bacteremia, particularly in the setting of infection due to MRSA [
         <a href="#rid102">
          102
         </a>
         ].
        </p>
        <p>
         The presence of prosthetic material or devices in a patient with
         <em>
          S. aureus
         </em>
         increases the risk of relapsed infection. This was illustrated in a series of 294 patients with
         <em>
          S. aureus
         </em>
         bacteremia; relapses occur more frequently among patients with an indwelling foreign body (83 versus 21 percent) [
         <a href="#rid72">
          72
         </a>
         ]. The median time to relapse after the first detected bacteremic episode in patients with retained foreign bodies was 69 days (range 35 to 89 days). The proportion of patients with
         <em>
          S. aureus
         </em>
         bacteremia who have a permanent prosthetic device has increased over time. In one cohort including more than 2300 patients with
         <em>
          S. aureus
         </em>
         bacteremia enrolled between 1995 and 2015, more than half had an indwelling prosthetic device [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3158021455">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/110550.html" rel="external">
          "Society guideline links: Management of
          <i>
           Staphylococcus aureus
          </i>
          infection"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H12437020">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topic (see
         <a class="medical medical_basics" href="/z/d/html/16928.html" rel="external">
          "Patient education: Sepsis in adults (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H19">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical approach
         </strong>
         − The clinical approach to
         <em>
          Staphylococcus aureus
         </em>
         bacteremia consists of careful history and physical examination, infectious disease consultation, and diagnostic evaluation including echocardiography and additional imaging as needed. (See
         <a class="local">
          'Clinical approach'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          History and physical examination
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Clinical history
         </strong>
         − Patients should be questioned regarding potential portals of entry, presence of indwelling prosthetic devices, and symptoms that may reflect metastatic infection. These include bone or joint pain (particularly back pain, suggesting vertebral osteomyelitis, discitis, and/or epidural abscess) and protracted fever and/or sweats (suggestive of endocarditis). (See
         <a class="local">
          'History and physical examination'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Physical examination
         </strong>
         − The physical examination should include cardiac examination for signs of new murmurs or heart failure. A search should be undertaken for clinical stigmata of endocarditis, including evidence of small and large emboli. Serial bedside examinations are critical for detection of complications that may develop after initial evaluation and during the course of treatment. (See
         <a class="local">
          'History and physical examination'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Infectious disease consultation
         </strong>
         − We recommend bedside infectious disease consultation for management of patients with
         <em>
          S. aureus
         </em>
         bacteremia (
         <a class="grade" href="https:///uptodate/show/grade_2" rel="external">
          Grade 1B
         </a>
         ); this is a critical component of management for patients with
         <em>
          S. aureus
         </em>
         bacteremia and is associated with better outcomes including fewer deaths, fewer relapses, and lower readmission rates. (See
         <a class="local">
          'Infectious disease consultation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnostic evaluation
         </strong>
         − In general, blood cultures positive for
         <em>
          S. aureus
         </em>
         should be respected as a clinically significant finding that should prompt clinical evaluation and initiation of empiric therapy. All patients with
         <em>
          S. aureus
         </em>
         bacteremia should undergo echocardiography to evaluate for presence of endocarditis. Additional diagnostic imaging should be tailored to findings on history and physical examination. (See
         <a class="local">
          'Diagnostic evaluation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Empiric treatment
         </strong>
         − In the setting of blood cultures with gram-positive cocci prior to availability of culture and susceptibility data, we suggest administration of empiric antimicrobial therapy with activity against methicillin resistant
         <em>
          S. aureus
         </em>
         (MRSA), rather than empiric therapy with activity against both MRSA and methicillin-sensitive
         <em>
          S. aureus
         </em>
         (MSSA) (
         <a class="grade" href="https:///uptodate/show/grade_5" rel="external">
          Grade 2B
         </a>
         ). Empiric treatment consists of
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         (
         <a class="graphic graphic_table graphicRef128911" href="/z/d/graphic/128911.html" rel="external">
          table 2
         </a>
         );
         <a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">
          daptomycin
         </a>
         is an acceptable alternative agent. (See
         <a class="local">
          'Empiric antibiotic therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Tailored treatment
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          MSSA
         </strong>
         − (see
         <a class="local">
          'Methicillin-sensitive S. aureus'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         We recommend treating MSSA bacteremia with a beta-lactam antibiotic (in preference to
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         or
         <a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">
          daptomycin
         </a>
         ) (
         <a class="grade" href="https:///uptodate/show/grade_2" rel="external">
          Grade 1B
         </a>
         ). Regimens include penicillin,
         <a class="drug drug_general" data-topicid="9674" href="/z/d/drug information/9674.html" rel="external">
          nafcillin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9724" href="/z/d/drug information/9724.html" rel="external">
          oxacillin
         </a>
         , flucloxacillin, or
         <a class="drug drug_general" data-topicid="9214" href="/z/d/drug information/9214.html" rel="external">
          cefazolin
         </a>
         .
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          Vancomycin
         </a>
         is less effective for treatment of
         <em>
          S. aureus
         </em>
         bacteremia than beta-lactam agents and should not be administered as primary therapy for methicillin-sensitive strains unless the use of a beta-lactam agent is precluded by drug intolerance.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         There is no role for routine combination therapy of antistaphylococcal penicillins or
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         with aminoglycosides,
         <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">
          rifampin
         </a>
         , or
         <a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">
          daptomycin
         </a>
         for treatment of
         <em>
          S. aureus
         </em>
         bacteremia.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          MRSA
         </strong>
         − The treatment of patients with bacteremia due to MRSA is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/3164.html" rel="external">
          "Methicillin-resistant Staphylococcus aureus (MRSA) in adults: Treatment of bacteremia", section on 'Antimicrobial therapy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Parenteral versus oral therapy
         </strong>
         – For patients with uncomplicated
         <em>
          S. aureus
         </em>
         bacteremia, standard treatment consists of parenteral therapy. It is uncertain whether treatment may be completed with an oral antibiotic regimen in some circumstances; further well-designed clinical trials are needed. (See
         <a class="local">
          'Parenteral versus oral therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Duration of therapy
         </strong>
         − The duration of therapy depends on the etiology of infection. In general, patients with bacteremia with a removable focus of infection may be treated with 14 days of therapy. (See
         <a class="local">
          'Duration of therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1230661046">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff at acknowledges Daniel Sexton, MD, who contributed to earlier versions of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Souli M, Ruffin F, Choi SH, et al. Changing Characteristics of Staphylococcus aureus Bacteremia: Results From a 21-Year, Prospective, Longitudinal Study. Clin Infect Dis 2019; 69:1868.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jensen AG, Espersen F, Skinhøj P, Frimodt-Møller N. Bacteremic Staphylococcus aureus spondylitis. Arch Intern Med 1998; 158:509.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Danner RL, Hartman BJ. Update on spinal epidural abscess: 35 cases and review of the literature. Rev Infect Dis 1987; 9:265.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Darouiche RO, Hamill RJ, Greenberg SB, et al. Bacterial spinal epidural abscess. Review of 43 cases and literature survey. Medicine (Baltimore) 1992; 71:369.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jernigan JA, Farr BM. Short-course therapy of catheter-related Staphylococcus aureus bacteremia: a meta-analysis. Ann Intern Med 1993; 119:304.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rieg S, Peyerl-Hoffmann G, de With K, et al. Mortality of S. aureus bacteremia and infectious diseases specialist consultation--a study of 521 patients in Germany. J Infect 2009; 59:232.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fowler VG Jr, Sanders LL, Sexton DJ, et al. Outcome of Staphylococcus aureus bacteremia according to compliance with recommendations of infectious diseases specialists: experience with 244 patients. Clin Infect Dis 1998; 27:478.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Forsblom E, Ruotsalainen E, Ollgren J, Järvinen A. Telephone consultation cannot replace bedside infectious disease consultation in the management of Staphylococcus aureus Bacteremia. Clin Infect Dis 2013; 56:527.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bai AD, Showler A, Burry L, et al. Impact of Infectious Disease Consultation on Quality of Care, Mortality, and Length of Stay in Staphylococcus aureus Bacteremia: Results From a Large Multicenter Cohort Study. Clin Infect Dis 2015; 60:1451.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vogel M, Schmitz RP, Hagel S, et al. Infectious disease consultation for Staphylococcus aureus bacteremia - A systematic review and meta-analysis. J Infect 2016; 72:19.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goto M, Schweizer ML, Vaughan-Sarrazin MS, et al. Association of Evidence-Based Care Processes With Mortality in Staphylococcus aureus Bacteremia at Veterans Health Administration Hospitals, 2003-2014. JAMA Intern Med 2017; 177:1489.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weis S, Hagel S, Palm J, et al. Effect of Automated Telephone Infectious Disease Consultations to Nonacademic Hospitals on 30-Day Mortality Among Patients With Staphylococcus aureus Bacteremia: The SUPPORT Cluster Randomized Clinical Trial. JAMA Netw Open 2022; 5:e2218515.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Go JR, Challener D, Corsini Campioli C, et al. Clinical Significance of Staphylococcus aureus in a Single Positive Blood Culture Bottle. Open Forum Infect Dis 2022; 9:ofab642.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kuehl R, Morata L, Boeing C, et al. Defining persistent Staphylococcus aureus bacteraemia: secondary analysis of a prospective cohort study. Lancet Infect Dis 2020; 20:1409.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Holland TL, Arnold C, Fowler VG Jr. Clinical management of Staphylococcus aureus bacteremia: a review. JAMA 2014; 312:1330.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011; 52:e18.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaasch AJ, Fowler VG Jr, Rieg S, et al. Use of a simple criteria set for guiding echocardiography in nosocomial Staphylococcus aureus bacteremia. Clin Infect Dis 2011; 53:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rasmussen RV, Høst U, Arpi M, et al. Prevalence of infective endocarditis in patients with Staphylococcus aureus bacteraemia: the value of screening with echocardiography. Eur J Echocardiogr 2011; 12:414.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fowler VG Jr, Li J, Corey GR, et al. Role of echocardiography in evaluation of patients with Staphylococcus aureus bacteremia: experience in 103 patients. J Am Coll Cardiol 1997; 30:1072.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Khatib R, Sharma M. Echocardiography is dispensable in uncomplicated Staphylococcus aureus bacteremia. Medicine (Baltimore) 2013; 92:182.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barton T, Moir S, Rehmani H, et al. Low rates of endocarditis in healthcare-associated Staphylococcus aureus bacteremia suggest that echocardiography might not always be required. Eur J Clin Microbiol Infect Dis 2016; 35:49.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abraham J, Mansour C, Veledar E, et al. Staphylococcus aureus bacteremia and endocarditis: the Grady Memorial Hospital experience with methicillin-sensitive S aureus and methicillin-resistant S aureus bacteremia. Am Heart J 2004; 147:536.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sullenberger AL, Avedissian LS, Kent SM. Importance of transesophageal echocardiography in the evaluation of Staphylococcus aureus bacteremia. J Heart Valve Dis 2005; 14:23.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Incani A, Hair C, Purnell P, et al. Staphylococcus aureus bacteraemia: evaluation of the role of transoesophageal echocardiography in identifying clinically unsuspected endocarditis. Eur J Clin Microbiol Infect Dis 2013; 32:1003.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rosen AB, Fowler VG Jr, Corey GR, et al. Cost-effectiveness of transesophageal echocardiography to determine the duration of therapy for intravascular catheter-associated Staphylococcus aureus bacteremia. Ann Intern Med 1999; 130:810.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sochowski RA, Chan KL. Implication of negative results on a monoplane transesophageal echocardiographic study in patients with suspected infective endocarditis. J Am Coll Cardiol 1993; 21:216.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Khandheria BK, Seward JB, Tajik AJ. Transesophageal echocardiography. Mayo Clin Proc 1994; 69:856.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Showler A, Burry L, Bai AD, et al. Use of Transthoracic Echocardiography in the Management of Low-Risk Staphylococcus aureus Bacteremia: Results From a Retrospective Multicenter Cohort Study. JACC Cardiovasc Imaging 2015; 8:924.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kahn F, Resman F, Bergmark S, et al. Time to blood culture positivity in Staphylococcus aureus bacteraemia to determine risk of infective endocarditis. Clin Microbiol Infect 2021; 27:1345.e7.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Simos PA, Holland DJ, Stewart A, et al. Clinical prediction scores and the utility of time to blood culture positivity in stratifying the risk of infective endocarditis in Staphylococcus aureus bacteraemia. J Antimicrob Chemother 2022; 77:2003.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sinclair MR, Souli M, Ruffin F, et al. Staphylococcus aureus Bacteremia Among Patients Receiving Maintenance Hemodialysis: Trends in Clinical Characteristics and Outcomes. Am J Kidney Dis 2022; 79:393.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bai AD, Agarwal A, Steinberg M, et al. Clinical predictors and clinical prediction rules to estimate initial patient risk for infective endocarditis in Staphylococcus aureus bacteraemia: a systematic review and meta-analysis. Clin Microbiol Infect 2017; 23:900.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tubiana S, Duval X, Alla F, et al. The VIRSTA score, a prediction score to estimate risk of infective endocarditis and determine priority for echocardiography in patients with Staphylococcus aureus bacteremia. J Infect 2016; 72:544.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abu Saleh O, Fida M, Asbury K, et al. Prospective Validation of PREDICT and Its Impact on the Transesophageal Echocardiography Use in Management of Staphylococcus aureus Bacteremia. Clin Infect Dis 2021; 73:e1745.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Siméon S, Le Moing V, Tubiana S, et al. Time to blood culture positivity: An independent predictor of infective endocarditis and mortality in patients with Staphylococcus aureus bacteraemia. Clin Microbiol Infect 2019; 25:481.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Peinado-Acevedo JS, Hurtado-Guerra JJ, Hincapié-Osorno C, et al. Validation of VIRSTA and PREDICT scores to determine the priority of echocardiography in patients with Staphylococcus aureus bacteremia. Clin Infect Dis 2021.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heriot GS, Tong SYC, Cheng AC, Liew D. A Scenario-Based Survey of Expert Echocardiography Recommendations for Patients With Staphylococcus aureus Bacteremia at Varying Risk for Endocarditis. JAMA Netw Open 2020; 3:e202401.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Palraj BR, Baddour LM, Hess EP, et al. Predicting Risk of Endocarditis Using a Clinical Tool (PREDICT): Scoring System to Guide Use of Echocardiography in the Management of Staphylococcus aureus Bacteremia. Clin Infect Dis 2015; 61:18.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van der Vaart TW, Prins JM, Soetekouw R, et al. Prediction Rules for Ruling Out Endocarditis in Patients With Staphylococcus aureus Bacteremia. Clin Infect Dis 2022; 74:1442.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ghanem-Zoubi N, Kagna O, Abu-Elhija J, et al. Integration of FDG-PET/CT in the Diagnostic Workup for Staphylococcus aureus Bacteremia: A Prospective Interventional Matched-cohort Study. Clin Infect Dis 2021; 73:e3859.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thottacherry E, Cortés-Penfield NW. Evidence of Clinical Impact Supports a New Petition for Medicare Coverage of 2-[18F]Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography/Computed Tomography in the Evaluation of Staphylococcus aureus Bacteremia: A Focused Literature Review and Call to Action. Clin Infect Dis 2022; 75:1457.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van der Vaart TW, Prins JM, van Werkhoven CH, et al. Positive Impact of [18F]FDG-PET/CT on Mortality in Patients With Staphylococcus aureus Bacteremia Explained by Immortal Time Bias. Clin Infect Dis 2023; 77:9.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           López-Cortés LE, Del Toro MD, Gálvez-Acebal J, et al. Impact of an evidence-based bundle intervention in the quality-of-care management and outcome of Staphylococcus aureus bacteremia. Clin Infect Dis 2013; 57:1225.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Minejima E, Mai N, Bui N, et al. Defining the Breakpoint Duration of Staphylococcus aureus Bacteremia Predictive of Poor Outcomes. Clin Infect Dis 2020; 70:566.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McConeghy KW, Bleasdale SC, Rodvold KA. The empirical combination of vancomycin and a β-lactam for Staphylococcal bacteremia. Clin Infect Dis 2013; 57:1760.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim SH, Kim KH, Kim HB, et al. Outcome of vancomycin treatment in patients with methicillin-susceptible Staphylococcus aureus bacteremia. Antimicrob Agents Chemother 2008; 52:192.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Davis JS, Sud A, O'Sullivan MV, et al. Combination of Vancomycin and β-Lactam Therapy for Methicillin-Resistant Staphylococcus aureus Bacteremia: A Pilot Multicenter Randomized Controlled Trial. Clin Infect Dis 2016; 62:173.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Khatib R, Saeed S, Sharma M, et al. Impact of initial antibiotic choice and delayed appropriate treatment on the outcome of Staphylococcus aureus bacteremia. Eur J Clin Microbiol Infect Dis 2006; 25:181.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lodise TP Jr, McKinnon PS, Levine DP, Rybak MJ. Impact of empirical-therapy selection on outcomes of intravenous drug users with infective endocarditis caused by methicillin-susceptible Staphylococcus aureus. Antimicrob Agents Chemother 2007; 51:3731.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stryjewski ME, Szczech LA, Benjamin DK Jr, et al. Use of vancomycin or first-generation cephalosporins for the treatment of hemodialysis-dependent patients with methicillin-susceptible Staphylococcus aureus bacteremia. Clin Infect Dis 2007; 44:190.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McDanel JS, Perencevich EN, Diekema DJ, et al. Comparative effectiveness of beta-lactams versus vancomycin for treatment of methicillin-susceptible Staphylococcus aureus bloodstream infections among 122 hospitals. Clin Infect Dis 2015; 61:361.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sutherland R, Croydon EA, Rolinson GN. Flucloxacillin, a new isoxazolyl penicillin, compared with oxacillin, cloxacillin, and dicloxacillin. Br Med J 1970; 4:455.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nissen JL, Skov R, Knudsen JD, et al. Effectiveness of penicillin, dicloxacillin and cefuroxime for penicillin-susceptible Staphylococcus aureus bacteraemia: a retrospective, propensity-score-adjusted case-control and cohort analysis. J Antimicrob Chemother 2013; 68:1894.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lowy FD. Staphylococcus aureus infections. N Engl J Med 1998; 339:520.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Resman F, Thegerström J, Månsson F, et al. The prevalence, population structure and screening test specificity of penicillin-susceptible Staphylococcus aureus bacteremia isolates in Malmö, Sweden. J Infect 2016; 73:129.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Crane JK. Resurgence of penicillin-susceptible Staphylococcus aureus at a hospital in New York State, USA. J Antimicrob Chemother 2014; 69:280.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Henderson A, Cheng MP, Chew KL, et al. A multi-site, international laboratory study to assess the performance of penicillin susceptibility testing of Staphylococcus aureus. J Antimicrob Chemother 2023; 78:1499.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Youngster I, Shenoy ES, Hooper DC, Nelson SB. Comparative evaluation of the tolerability of cefazolin and nafcillin for treatment of methicillin-susceptible Staphylococcus aureus infections in the outpatient setting. Clin Infect Dis 2014; 59:369.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Li J, Echevarria KL, Hughes DW, et al. Comparison of cefazolin versus oxacillin for treatment of complicated bacteremia caused by methicillin-susceptible Staphylococcus aureus. Antimicrob Agents Chemother 2014; 58:5117.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bai AD, Showler A, Burry L, et al. Comparative effectiveness of cefazolin versus cloxacillin as definitive antibiotic therapy for MSSA bacteraemia: results from a large multicentre cohort study. J Antimicrob Chemother 2015; 70:1539.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee S, Choe PG, Song KH, et al. Is cefazolin inferior to nafcillin for treatment of methicillin-susceptible Staphylococcus aureus bacteremia? Antimicrob Agents Chemother 2011; 55:5122.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weis S, Kesselmeier M, Davis JS, et al. Cefazolin versus anti-staphylococcal penicillins for the treatment of patients with Staphylococcus aureus bacteraemia. Clin Microbiol Infect 2019; 25:818.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bidell MR, Patel N, O'Donnell JN. Optimal treatment of MSSA bacteraemias: a meta-analysis of cefazolin versus antistaphylococcal penicillins. J Antimicrob Chemother 2018; 73:2643.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McDanel JS, Roghmann MC, Perencevich EN, et al. Comparative Effectiveness of Cefazolin Versus Nafcillin or Oxacillin for Treatment of Methicillin-Susceptible Staphylococcus aureus Infections Complicated by Bacteremia: A Nationwide Cohort Study. Clin Infect Dis 2017; 65:100.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miller WR, Seas C, Carvajal LP, et al. The Cefazolin Inoculum Effect Is Associated With Increased Mortality in Methicillin-Susceptible Staphylococcus aureus Bacteremia. Open Forum Infect Dis 2018; 5:ofy123.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dingle TC, Gamage D, Gomez-Villegas S, et al. Prevalence and Characterization of the Cefazolin Inoculum Effect in North American Methicillin-Susceptible Staphylococcus aureus Isolates. J Clin Microbiol 2022; 60:e0249521.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Loubet P, Burdet C, Vindrios W, et al. Cefazolin versus anti-staphylococcal penicillins for treatment of methicillin-susceptible Staphylococcus aureus bacteraemia: a narrative review. Clin Microbiol Infect 2018; 24:125.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Regamey C, Libke RD, Engelking ER, et al. Inactivation of cefazolin, cephaloridine, and cephalothin by methicillin-sensitive and methicillin-resistant strains of Staphylococcus aureus. J Infect Dis 1975; 131:291.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nannini EC, Stryjewski ME, Singh KV, et al. Inoculum effect with cefazolin among clinical isolates of methicillin-susceptible Staphylococcus aureus: frequency and possible cause of cefazolin treatment failure. Antimicrob Agents Chemother 2009; 53:3437.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nannini EC, Stryjewski ME, Singh KV, et al. Determination of an inoculum effect with various cephalosporins among clinical isolates of methicillin-susceptible Staphylococcus aureus. Antimicrob Agents Chemother 2010; 54:2206.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hartstein AI, Mulligan ME, Morthland VH, Kwok RY. Recurrent Staphylococcus aureus bacteremia. J Clin Microbiol 1992; 30:670.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fowler VG Jr, Kong LK, Corey GR, et al. Recurrent Staphylococcus aureus bacteremia: pulsed-field gel electrophoresis findings in 29 patients. J Infect Dis 1999; 179:1157.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Karchmer AW. Staphylococcus aureus and vancomycin: the sequel. Ann Intern Med 1991; 115:739.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Levine DP, Fromm BS, Reddy BR. Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis. Ann Intern Med 1991; 115:674.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mortara LA, Bayer AS. Staphylococcus aureus bacteremia and endocarditis. New diagnostic and therapeutic concepts. Infect Dis Clin North Am 1993; 7:53.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Small PM, Chambers HF. Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users. Antimicrob Agents Chemother 1990; 34:1227.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chang FY, Peacock JE Jr, Musher DM, et al. Staphylococcus aureus bacteremia: recurrence and the impact of antibiotic treatment in a prospective multicenter study. Medicine (Baltimore) 2003; 82:333.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stevens DL. The role of vancomycin in the treatment paradigm. Clin Infect Dis 2006; 42 Suppl 1:S51.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           González C, Rubio M, Romero-Vivas J, et al. Bacteremic pneumonia due to Staphylococcus aureus: A comparison of disease caused by methicillin-resistant and methicillin-susceptible organisms. Clin Infect Dis 1999; 29:1171.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gentry CA, Rodvold KA, Novak RM, et al. Retrospective evaluation of therapies for Staphylococcus aureus endocarditis. Pharmacotherapy 1997; 17:990.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Blumenthal KG, Parker RA, Shenoy ES, Walensky RP. Improving Clinical Outcomes in Patients With Methicillin-Sensitive Staphylococcus aureus Bacteremia and Reported Penicillin Allergy. Clin Infect Dis 2015; 61:741.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Copaescu AM, Vogrin S, James F, et al. Efficacy of a Clinical Decision Rule to Enable Direct Oral Challenge in Patients With Low-Risk Penicillin Allergy: The PALACE Randomized Clinical Trial. JAMA Intern Med 2023; 183:944.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Korzeniowski O, Sande MA. Combination antimicrobial therapy for Staphylococcus aureus endocarditis in patients addicted to parenteral drugs and in nonaddicts: A prospective study. Ann Intern Med 1982; 97:496.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fowler VG Jr, Boucher HW, Corey GR, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 2006; 355:653.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cosgrove SE, Vigliani GA, Fowler VG Jr, et al. Initial low-dose gentamicin for Staphylococcus aureus bacteremia and endocarditis is nephrotoxic. Clin Infect Dis 2009; 48:713.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thwaites GE, Scarborough M, Szubert A, et al. Adjunctive rifampicin for Staphylococcus aureus bacteraemia (ARREST): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet 2018; 391:668.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cheng MP, Lawandi A, Butler-Laporte G, et al. Adjunctive Daptomycin in the Treatment of Methicillin-susceptible Staphylococcus aureus Bacteremia: A Randomized, Controlled Trial. Clin Infect Dis 2021; 72:e196.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hazen KC, Polage CR. Using Data to Optimize Blood Bottle Fill Volumes and Pathogen Detection: Making Blood Cultures Great Again. Clin Infect Dis 2020; 70:269.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stewart JD, Graham M, Kotsanas D, et al. Intermittent Negative Blood Cultures in Staphylococcus aureus Bacteremia; a Retrospective Study of 1071 Episodes. Open Forum Infect Dis 2019; 6:ofz494.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dagher M, Fowler VG Jr, Wright PW, Staub MB. A Narrative Review of Early Oral Stepdown Therapy for the Treatment of Uncomplicated Staphylococcus aureus Bacteremia: Yay or Nay? Open Forum Infect Dis 2020; 7:ofaa151.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Iversen K, Ihlemann N, Gill SU, et al. Partial Oral versus Intravenous Antibiotic Treatment of Endocarditis. N Engl J Med 2019; 380:415.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mermel LA, Allon M, Bouza E, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 49:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chong YP, Moon SM, Bang KM, et al. Treatment duration for uncomplicated Staphylococcus aureus bacteremia to prevent relapse: analysis of a prospective observational cohort study. Antimicrob Agents Chemother 2013; 57:1150.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Holland TL, Raad I, Boucher HW, et al. Effect of Algorithm-Based Therapy vs Usual Care on Clinical Success and Serious Adverse Events in Patients with Staphylococcal Bacteremia: A Randomized Clinical Trial. JAMA 2018; 320:1249.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thorlacius-Ussing L, Sandholdt H, Nissen J, et al. Comparable Outcomes of Short-Course and Prolonged-Course Therapy in Selected Cases of Methicillin-Susceptible Staphylococcus aureus Bacteremia: A Pooled Cohort Study. Clin Infect Dis 2021; 73:866.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tong SYC, Walls G. Shortening the Duration of Therapy for Staphylococcus aureus Bacteremia: Opening the Overton Window. Clin Infect Dis 2021; 73:873.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bai AD, Lo CKL, Komorowski AS, et al. Staphylococcus aureus bacteraemia mortality: a systematic review and meta-analysis. Clin Microbiol Infect 2022; 28:1076.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Hal SJ, Jensen SO, Vaska VL, et al. Predictors of mortality in Staphylococcus aureus Bacteremia. Clin Microbiol Rev 2012; 25:362.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gopal AK, Fowler VG Jr, Shah M, et al. Prospective analysis of Staphylococcus aureus bacteremia in nonneutropenic adults with malignancy. J Clin Oncol 2000; 18:1110.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lesens O, Methlin C, Hansmann Y, et al. Role of comorbidity in mortality related to Staphylococcus aureus bacteremia: a prospective study using the Charlson weighted index of comorbidity. Infect Control Hosp Epidemiol 2003; 24:890.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marra AR, Edmond MB, Forbes BA, et al. Time to blood culture positivity as a predictor of clinical outcome of Staphylococcus aureus bloodstream infection. J Clin Microbiol 2006; 44:1342.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Inagaki K, Lucar J, Blackshear C, Hobbs CV. Methicillin-susceptible and Methicillin-resistant Staphylococcus aureus Bacteremia: Nationwide Estimates of 30-Day Readmission, In-hospital Mortality, Length of Stay, and Cost in the United States. Clin Infect Dis 2019; 69:2112.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 2134 Version 72.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31001618" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Changing Characteristics of Staphylococcus aureus Bacteremia: Results From a 21-Year, Prospective, Longitudinal Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9508229" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Bacteremic Staphylococcus aureus spondylitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3589332" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Update on spinal epidural abscess: 35 cases and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1359381" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Bacterial spinal epidural abscess. Review of 43 cases and literature survey.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8328740" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Short-course therapy of catheter-related Staphylococcus aureus bacteremia: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19654021" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Mortality of S. aureus bacteremia and infectious diseases specialist consultation--a study of 521 patients in Germany.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9770144" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Outcome of Staphylococcus aureus bacteremia according to compliance with recommendations of infectious diseases specialists: experience with 244 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23087397" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Telephone consultation cannot replace bedside infectious disease consultation in the management of Staphylococcus aureus Bacteremia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25701854" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Impact of Infectious Disease Consultation on Quality of Care, Mortality, and Length of Stay in Staphylococcus aureus Bacteremia: Results From a Large Multicenter Cohort Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26453841" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Infectious disease consultation for Staphylococcus aureus bacteremia - A systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28873140" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Association of Evidence-Based Care Processes With Mortality in Staphylococcus aureus Bacteremia at Veterans Health Administration Hospitals, 2003-2014.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35749114" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Effect of Automated Telephone Infectious Disease Consultations to Nonacademic Hospitals on 30-Day Mortality Among Patients With Staphylococcus aureus Bacteremia: The SUPPORT Cluster Randomized Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35071685" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Clinical Significance of Staphylococcus aureus in a Single Positive Blood Culture Bottle.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32763194" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Defining persistent Staphylococcus aureus bacteraemia: secondary analysis of a prospective cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25268440" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Clinical management of Staphylococcus aureus bacteremia: a review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21208910" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21653295" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Use of a simple criteria set for guiding echocardiography in nosocomial Staphylococcus aureus bacteremia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21685200" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Prevalence of infective endocarditis in patients with Staphylococcus aureus bacteraemia: the value of screening with echocardiography.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9316542" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Role of echocardiography in evaluation of patients with Staphylococcus aureus bacteremia: experience in 103 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23619238" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Echocardiography is dispensable in uncomplicated Staphylococcus aureus bacteremia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26490139" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Low rates of endocarditis in healthcare-associated Staphylococcus aureus bacteremia suggest that echocardiography might not always be required.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14999206" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Staphylococcus aureus bacteremia and endocarditis: the Grady Memorial Hospital experience with methicillin-sensitive S aureus and methicillin-resistant S aureus bacteremia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15700431" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Importance of transesophageal echocardiography in the evaluation of Staphylococcus aureus bacteremia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23417650" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Staphylococcus aureus bacteraemia: evaluation of the role of transoesophageal echocardiography in identifying clinically unsuspected endocarditis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10366370" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Cost-effectiveness of transesophageal echocardiography to determine the duration of therapy for intravascular catheter-associated Staphylococcus aureus bacteremia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8417064" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Implication of negative results on a monoplane transesophageal echocardiographic study in patients with suspected infective endocarditis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8065188" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Transesophageal echocardiography.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26189120" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Use of Transthoracic Echocardiography in the Management of Low-Risk Staphylococcus aureus Bacteremia: Results From a Retrospective Multicenter Cohort Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33197608" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Time to blood culture positivity in Staphylococcus aureus bacteraemia to determine risk of infective endocarditis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35425988" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Clinical prediction scores and the utility of time to blood culture positivity in stratifying the risk of infective endocarditis in Staphylococcus aureus bacteraemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34303771" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Staphylococcus aureus Bacteremia Among Patients Receiving Maintenance Hemodialysis: Trends in Clinical Characteristics and Outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28487168" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Clinical predictors and clinical prediction rules to estimate initial patient risk for infective endocarditis in Staphylococcus aureus bacteraemia: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26916042" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : The VIRSTA score, a prediction score to estimate risk of infective endocarditis and determine priority for echocardiography in patients with Staphylococcus aureus bacteremia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32569366" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Prospective Validation of PREDICT and Its Impact on the Transesophageal Echocardiography Use in Management of Staphylococcus aureus Bacteremia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30036664" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Time to blood culture positivity: An independent predictor of infective endocarditis and mortality in patients with Staphylococcus aureus bacteraemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33537758" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Validation of VIRSTA and PREDICT scores to determine the priority of echocardiography in patients with Staphylococcus aureus bacteremia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32271391" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : A Scenario-Based Survey of Expert Echocardiography Recommendations for Patients With Staphylococcus aureus Bacteremia at Varying Risk for Endocarditis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25810284" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Predicting Risk of Endocarditis Using a Clinical Tool (PREDICT): Scoring System to Guide Use of Echocardiography in the Management of Staphylococcus aureus Bacteremia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34272564" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Prediction Rules for Ruling Out Endocarditis in Patients With Staphylococcus aureus Bacteremia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32639560" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Integration of FDG-PET/CT in the Diagnostic Workup for Staphylococcus aureus Bacteremia: A Prospective Interventional Matched-cohort Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35535794" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Evidence of Clinical Impact Supports a New Petition for Medicare Coverage of 2-[18F]Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography/Computed Tomography in the Evaluation of Staphylococcus aureus Bacteremia: A Focused Literature Review and Call to Action.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36869816" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Positive Impact of [18F]FDG-PET/CT on Mortality in Patients With Staphylococcus aureus Bacteremia Explained by Immortal Time Bias.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23929889" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Impact of an evidence-based bundle intervention in the quality-of-care management and outcome of Staphylococcus aureus bacteremia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30949675" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Defining the Breakpoint Duration of Staphylococcus aureus Bacteremia Predictive of Poor Outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23985343" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : The empirical combination of vancomycin and aβ-lactam for Staphylococcal bacteremia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17984229" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Outcome of vancomycin treatment in patients with methicillin-susceptible Staphylococcus aureus bacteremia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26349552" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Combination of Vancomycin andβ-Lactam Therapy for Methicillin-Resistant Staphylococcus aureus Bacteremia: A Pilot Multicenter Randomized Controlled Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16505987" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Impact of initial antibiotic choice and delayed appropriate treatment on the outcome of Staphylococcus aureus bacteremia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17664322" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Impact of empirical-therapy selection on outcomes of intravenous drug users with infective endocarditis caused by methicillin-susceptible Staphylococcus aureus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17173215" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Use of vancomycin or first-generation cephalosporins for the treatment of hemodialysis-dependent patients with methicillin-susceptible Staphylococcus aureus bacteremia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25900170" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Comparative effectiveness of beta-lactams versus vancomycin for treatment of methicillin-susceptible Staphylococcus aureus bloodstream infections among 122 hospitals.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5481218" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Flucloxacillin, a new isoxazolyl penicillin, compared with oxacillin, cloxacillin, and dicloxacillin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23599360" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Effectiveness of penicillin, dicloxacillin and cefuroxime for penicillin-susceptible Staphylococcus aureus bacteraemia: a retrospective, propensity-score-adjusted case-control and cohort analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9709046" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Staphylococcus aureus infections.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27265236" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : The prevalence, population structure and screening test specificity of penicillin-susceptible Staphylococcus aureus bacteremia isolates in Malmö, Sweden.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23925938" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Resurgence of penicillin-susceptible Staphylococcus aureus at a hospital in New York State, USA.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37071589" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : A multi-site, international laboratory study to assess the performance of penicillin susceptibility testing of Staphylococcus aureus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24785233" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Comparative evaluation of the tolerability of cefazolin and nafcillin for treatment of methicillin-susceptible Staphylococcus aureus infections in the outpatient setting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24936596" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Comparison of cefazolin versus oxacillin for treatment of complicated bacteremia caused by methicillin-susceptible Staphylococcus aureus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25614044" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Comparative effectiveness of cefazolin versus cloxacillin as definitive antibiotic therapy for MSSA bacteraemia: results from a large multicentre cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21825299" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Is cefazolin inferior to nafcillin for treatment of methicillin-susceptible Staphylococcus aureus bacteremia?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30928559" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Cefazolin versus anti-staphylococcal penicillins for the treatment of patients with Staphylococcus aureus bacteraemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30085140" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Optimal treatment of MSSA bacteraemias: a meta-analysis of cefazolin versus antistaphylococcal penicillins.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28379314" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Comparative Effectiveness of Cefazolin Versus Nafcillin or Oxacillin for Treatment of Methicillin-Susceptible Staphylococcus aureus Infections Complicated by Bacteremia: A Nationwide Cohort Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29977970" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : The Cefazolin Inoculum Effect Is Associated With Increased Mortality in Methicillin-Susceptible Staphylococcus aureus Bacteremia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35578988" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Prevalence and Characterization of the Cefazolin Inoculum Effect in North American Methicillin-Susceptible Staphylococcus aureus Isolates.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28698037" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Cefazolin versus anti-staphylococcal penicillins for treatment of methicillin-susceptible Staphylococcus aureus bacteraemia: a narrative review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1039311" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Inactivation of cefazolin, cephaloridine, and cephalothin by methicillin-sensitive and methicillin-resistant strains of Staphylococcus aureus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19487449" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Inoculum effect with cefazolin among clinical isolates of methicillin-susceptible Staphylococcus aureus: frequency and possible cause of cefazolin treatment failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20211890" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Determination of an inoculum effect with various cephalosporins among clinical isolates of methicillin-susceptible Staphylococcus aureus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1551985" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Recurrent Staphylococcus aureus bacteremia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10191218" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Recurrent Staphylococcus aureus bacteremia: pulsed-field gel electrophoresis findings in 29 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1929043" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Staphylococcus aureus and vancomycin: the sequel.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1929035" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8463653" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Staphylococcus aureus bacteremia and endocarditis. New diagnostic and therapeutic concepts.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2393284" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14530782" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Staphylococcus aureus bacteremia: recurrence and the impact of antibiotic treatment in a prospective multicenter study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16323121" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : The role of vancomycin in the treatment paradigm.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10524959" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Bacteremic pneumonia due to Staphylococcus aureus: A comparison of disease caused by methicillin-resistant and methicillin-susceptible organisms.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9324187" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Retrospective evaluation of therapies for Staphylococcus aureus endocarditis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25991471" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Improving Clinical Outcomes in Patients With Methicillin-Sensitive Staphylococcus aureus Bacteremia and Reported Penicillin Allergy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37459086" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Efficacy of a Clinical Decision Rule to Enable Direct Oral Challenge in Patients With Low-Risk Penicillin Allergy: The PALACE Randomized Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6751182" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Combination antimicrobial therapy for Staphylococcus aureus endocarditis in patients addicted to parenteral drugs and in nonaddicts: A prospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16914701" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19207079" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Initial low-dose gentamicin for Staphylococcus aureus bacteremia and endocarditis is nephrotoxic.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29249276" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Adjunctive rifampicin for Staphylococcus aureus bacteraemia (ARREST): a multicentre, randomised, double-blind, placebo-controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32667982" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Adjunctive Daptomycin in the Treatment of Methicillin-susceptible Staphylococcus aureus Bacteremia: A Randomized, Controlled Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30901027" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Using Data to Optimize Blood Bottle Fill Volumes and Pathogen Detection: Making Blood Cultures Great Again.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32128336" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Intermittent Negative Blood Cultures in Staphylococcus aureus Bacteremia; a Retrospective Study of 1071 Episodes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32523971" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : A Narrative Review of Early Oral Stepdown Therapy for the Treatment of Uncomplicated Staphylococcus aureus Bacteremia: Yay or Nay?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30152252" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Partial Oral versus Intravenous Antibiotic Treatment of Endocarditis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19489710" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23254436" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Treatment duration for uncomplicated Staphylococcus aureus bacteremia to prevent relapse: analysis of a prospective observational cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30264119" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Effect of Algorithm-Based Therapy vs Usual Care on Clinical Success and Serious Adverse Events in Patients with Staphylococcal Bacteremia: A Randomized Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33677515" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Comparable Outcomes of Short-Course and Prolonged-Course Therapy in Selected Cases of Methicillin-Susceptible Staphylococcus aureus Bacteremia: A Pooled Cohort Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33675649" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Shortening the Duration of Therapy for Staphylococcus aureus Bacteremia: Opening the Overton Window.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35339678" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Staphylococcus aureus bacteraemia mortality: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22491776" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Predictors of mortality in Staphylococcus aureus Bacteremia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10694564" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Prospective analysis of Staphylococcus aureus bacteremia in nonneutropenic adults with malignancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14700403" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Role of comorbidity in mortality related to Staphylococcus aureus bacteremia: a prospective study using the Charlson weighted index of comorbidity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16597860" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Time to blood culture positivity as a predictor of clinical outcome of Staphylococcus aureus bloodstream infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30753447" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Methicillin-susceptible and Methicillin-resistant Staphylococcus aureus Bacteremia: Nationwide Estimates of 30-Day Readmission, In-hospital Mortality, Length of Stay, and Cost in the United States.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
